Discontinuation of Beta-Blocker Therapy after Myocardial Infarction.

Area of Science:

• Cardiology
• Clinical Trials
• Pharmacotherapy

Background:

• The necessity of long-term beta-blocker (BB) therapy post-myocardial infarction (MI) is uncertain in patients without left ventricular systolic dysfunction or heart failure, especially with modern reperfusion and secondary prevention strategies.
• Contemporary management of MI has evolved, prompting re-evaluation of established treatment protocols.

Purpose of the Study:

• To determine if discontinuing beta-blocker therapy beyond one year post-myocardial infarction is noninferior to continuing it in stable patients without heart failure.
• To assess the composite outcome of all-cause death, recurrent MI, or heart failure hospitalization.

Main Methods:

• An open-label, randomized, noninferiority trial involving 2540 stable patients post-MI with LVEF ≥40% and no heart failure, who had received BB therapy for at least 1 year.
• Patients were randomized 1:1 to either discontinue or continue beta-blocker therapy.
• The primary endpoint was a composite of death, recurrent MI, or heart failure hospitalization, with a noninferiority margin set at HR 1.4.

Main Results:

• A total of 2540 patients were randomized; 1246 to discontinuation and 1294 to continuation.
• At a median follow-up of 3.1 years, the 4-year event rate was 7.2% in the discontinuation group and 9.0% in the continuation group (HR 0.80; 95% CI 0.57-1.13).
• The study met its noninferiority endpoint (P=0.001), with similar rates of serious adverse events in both groups.

Conclusions:

• Discontinuation of beta-blocker therapy beyond one year post-myocardial infarction is noninferior to continuation in stable patients without heart failure.
• This finding supports a potential de-escalation of long-term beta-blocker therapy in select post-MI patients.
• The study provides crucial evidence for optimizing pharmacotherapy in cardiovascular secondary prevention.